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California, Irvine, Irvine,Fernand Braudel popularized the longue durée approach
to scholarly investigation in the mid-20th century. The lon-
gue durée approach can be loosely translated to mean “look
for the big picture, synthesize data collected using all avail-
able methodology over the long periods of time to identify
fundamental principles, rather than becoming preoccupied
with isolated observations.” Braudel, a historian and econ-
omist, emphasized observation of enduring historical
structures and analysis of long-term, panoramic economic
trends rather than concentrating on detailed descriptions of
particular events or individuals. He also urged the use of
insight gained frommany scholarly disciplines to identify the
essential underpinnings of social change [1].
Braudel’s longue durée approachmay also be useful in the
study atherosclerosis, which is among the most important
diseases affecting mankind. Cardiologists’ immediate atten-
tion is understandably focused on dealing with individual
patients and the current epidemic of atherosclerotic heart
disease, concentrating on applying the latest scientiﬁc
advances in diagnosis and treatment. A broader “big
picture” view of atherosclerosis includes observations made
throughout the lifetime of an individual, as the disease
evolves from a subclinical state to acute manifestations such
as chest pain, myocardial infarction, stroke, and sudden
death. Insightmay also be gained by studying atherosclerosis
in populations as well as in individuals, and over the entire
span of human existence, not just in contemporary society,
looking at the effects of widely varying environmental, cul-
tural, and societal conditions and evolving genomes.We can
also learn from studying atherosclerosis in creatures other
than Homo sapiens.
Like Braudel, physicians and biologists beneﬁt from
observationsmade using analyticmethods ofmany disparate
disciplines other than their own, including anthropology,
archeology, and the physical as well as biologic sciences. A
broad view is needed to better understand many of the key
features of atherosclerosis that may not be apparent looking
only at the patient immediately in front of us. Indeed, if we
are to counter the current global epidemic of atherosclerosis,
we need not only a knowledge of medicine—an under-
standing of the genomic, pathophysiologic, pharmacologic,
and nutritional aspects of atherosclerosis—but also knowl-
edge of the sociologic, economic, and cultural underpinningGLOBAL HEART, VOL. 9, NO. 2, 2014
June 2014: 239-244of the rapid changes now occurring in developing countries
of the world, where communicable diseases are being
replaced by heart disease and cancer as leading causes of
death and disability.PATHOLOGIC OBSERVATIONS OF
ATHEROSCLEROSIS
The protean pathophysiologic manifestations and extent of
atherosclerosis increase with advancing age [2e9]; they
begin early in life, and complications and clinical manifes-
tations occur later. Lobstein introduced the term “arterio-
sclerosis” in the early 19th century on the basis of autopsy
observation of gross pathologic anatomy. His observations
were expanded by the renowned pathologists Virchow and
von Rokitansky, who used similar detailed microscopic
analysis of postmortem specimens to come to diametrically
opposing views of the genesis of atherosclerosis. Virchow
held that cellular inﬂammatory changes observed in the
atherosclerotic vessel walls was of primary importance,
whereas von Rokitansky considered them secondary to hu-
moral disease.
Using 21st century histologic techniques, Mayerl et al.
[10] found immunohistochemical and immunoﬂuorescent
evidence of inﬂammation on several of von Rokitansky’s
original pathologic specimens, supporting Virchow’s belief
that inﬂammatory processes underlie the formation of
atherosclerosis, demonstrating that different conclusions
may be drawn by re-examining old data using new tech-
niques, again demonstrating the value of a longue durée
approach. In another analogy to historical methodology,
Leopold von Ranke fostered the concept of source-based
history (wie es eigentlich gewesen ist), re-examining and
reinterpreting original historical documents rather than
accepting the translations of others [11]. These expanded
histologic observations of inﬂammation in historic patho-
logic specimens are further supported by the use of newer
measures of inﬂammation, C-reactive protein, interleukin-
6, tumor necrosis factor, and other circulating markers
[12].
Pathologists [13,14] have created a robust literature
describing various anatomic features ascribed to athero-
sclerosis, including the use of terms such as: intimal239
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sclerosis; atheroma; Monckeberg medial sclerosis; focal
atherosclerosis; atherothrombosis; lipid-laden; ﬁbrotic and
ruptured plaques; and plaques that appear to be vulnerable
to future rupture, platelet aggregations, and acute throm-
bosis. Considerable evidence has accumulated to support
Virchow’s assertion that inﬂammation plays a key role in
the development of atherosclerosis [12]. Pathology was
among the earliest medical sciences and continues to
provide key insights, but a precise deﬁnition of athero-
sclerosis and clariﬁcation of its fundamental and proximate
causes and ultimate consequences for the whole, living
individual must include physiologic, biochemical, subcel-
lular, and genomic tools [14].BEYOND GROSS ANATOMY AND HISTOLOGY
Spectacular advances [15e17] in medical imaging over the
past 3 decades provide considerable insight into the patho-
physiology of atherosclerosis, acute coronary syndromes,
and other clinical consequences of atherosclerosis. Catheter-
based intravascular ultrasound and optical coherence to-
mography and noninvasive approaches using magnetic
resonance imaging, computed x-ray tomography, and nu-
clear imaging are all proving useful not only in deﬁning basic
biologic processes, but also aiding in the development of new
and more-effective treatments.
Evolving deﬁnitions of atherosclerosis should remind us
that methodological advances and increasing knowledge of
basic pathophysiologic mechanisms have long fostered
confusion and controversy over a precise deﬁnition of many
diseases, including atherosclerosis. A longue durée approach
to understanding atherosclerosis accounts for changes in
technology, perspective, and even the language and culture
of investigators and observers, which naturally vary over
time, as well as changes in the subjects and the disease
process itself. The longue durée approach teaches us that our
observations of a phenomenon may change as our power of
observation changes, and we must be careful not to confuse
these different descriptions with real changes in the phe-
nomenon being observed.ATHEROSCLEROSIS OCCURS EARLY IN LIFE AND
EARLY IN HUMAN HISTORY
Atherosclerosis not only starts early in life [2,3], even
during the prenatal period [18], but it has also been part of
the human condition for many thousands of years
[4e6,19e23]. Fatty atherosclerotic streaks have been
observed during post-mortem examinations of young
children [2,3], and in far more-advanced forms in young
adults dying of trauma. Atherosclerosis was present in 77%
of soldiers dying from trauma in the Korean War [7], 45%
in the Vietnam War [8], and 8.5% in the Iraq War [9]. This
decline tempts us to give credit to our modern public
health campaigns for reducing disease burden by encour-
aging healthy behavioral changes in smoking, dietary, and
exercise habits.But a careful analysis of the different methods used in
these studies, conducted during a period of rapid change in
medical technology, suggests that the deﬁnition of
atherosclerosis was not the same in these 3 groups of
young military personnel dying of war-related causes, and
a raw comparison of the incidence of atherosclerosis in the
3 groups is misleading. For instance, the Vietnam study
employed angiography of perfusion-ﬁxed coronary arteries
to diagnose atherosclerosis, whereas the Korean and Iraq
studies relied on direct visualization of atherosclerotic
plaques in the coronary arteries. The Korean study also
deﬁned microscopic evidence of arterial ﬁbrous thickening
as well as fatty streaking as evidence of atherosclerosis. In
this context, it is not surprising that few young, active
combat soldiers had angiographically apparent stenosis of
their coronary arteries, while they may well have had early
atherosclerotic lesions that did not impinge on the lumen
of the coronary artery. Both Braudel and von Ranke remind
us to look at our data critically over time.
With our focus on these and other scientiﬁc break-
throughs, superimposed on our current frightening
epidemic of obesity and diabetes, we often think of athero-
sclerosis as a modern disease, caused by dietary excess,
physical inactivity, and tobacco smoking. However, in 1852,
pathologist Johann Czermak [19] found evidence of calciﬁc
aortic atherosclerosis during the autopsy of the mummiﬁed
ancient remains of an Egyptian woman. In 1909, Samuel
Shattock [20] found atherosclerosis in the aorta of the Pha-
raohMenephtah, believed to have been the pharaoh referred
to in Exodus, and in 1911, Sir Marc Armond Ruffer [21]
published histologic evidence of atherosclerosis in multiple
3,000-year-old Egyptian mummies. A. T. Sandison [24]
subsequently demonstrated the presence of atherosclerosis
in arteries throughout the body in Egyptianmummies. More
recently, Michael Zimmerman [22] demonstrated athero-
sclerosis in naturally frozen mummies found in Alaska.
Zimmerman’s ﬁndings are particularly notable, as the cul-
tures in which these ancient humans lived did not practice
agriculture, but were hunter-gatherer-ﬁsher people. Because
of the destructive nature of the process, relatively few au-
topsies have been performed on ancient mummies.
Advances in medical imaging technology now allow us
to perform noninvasive, nondestructive “autopsies” in living
humans as well as long-dead mummies. X-ray computed
tomography (CT), which is exquisitely sensitive in detecting
calciﬁed deposits within atherosclerotic plaque [7], is
particularly well suited to providing epidemiologic insight
into both current and ancient populations. The presence and
degree of calciﬁcation of the coronary arteries asmeasured by
CT has been shown in large contemporary, multiethnic
population studies to be closely correlated with future cor-
onary events [25]. We, and others [4e6,23,24] have used
CT technology to detect evidence of atherosclerosis in
ancient human mummies from Egypt, Peru, the Americas,
the Aleutian Islands, and Europe.
Although it is clear that atherosclerosis has been in
human populations for thousands of years, progressingGLOBAL HEART, VOL. 9, NO. 2, 2014
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slowly from infancy to adulthood, this evidence is largely
related to observations of subclinical, asymptomatic dis-
ease. It was not until the 20th century that James Herrick
[26] recognized the relationship between obstruction of the
epicardial coronary arteries and acute myocardial infarc-
tion. Pre-dating Herrick’s insightful observations, many
clinical descriptions have been made of what were surely
symptoms of angina pectoris and acute myocardial
infarction, dating at least to 1555 BCE, when a scribe
entered the following vignette on what eventually came to
be known as the Ebers’ medical papyri [27]: “If thou
examist a man for illness in his cardia, and he has pains in
his arms, in his breasts and on one side of his cardia. it is
death threatening him.”
These observations in a relatively large number of
ancient humans alive over 4,000 years of human history and
living in a variety of cultures, including pre-agricultural
hunter-forager societies, raise serious questions about con-
ventional attribution of the risk of developing atherosclerosis
to diet and environment. Albert Zink and his colleagues
[23,28] made additional advances in our understanding of
human atherosclerosis by not only demonstrating CT evi-
dence of calciﬁc atherosclerosis in themummiﬁed remains of
the 5,300-year-old “Iceman,” but also showing that he had
several single nucleotide polymorphisms known to predis-
pose to atherosclerosis in contemporary humans. From the
longue durée perspective, our current epidemic of athero-
sclerosis may be but a blip on the evolutionary calendar. The
relationship between basic evolutionary biology and medi-
cine deserves more attention [29].MODERN DAY HUNTER-GATHERERS
Studies of the few remaining contemporary hunter-gatherer
populations may provide valuable insight into how our pre-
historic human ancestors lived and the kinds of diseases
including atherosclerosis that they may have developed
under far different environmental inﬂuences than are present
today. Contemporary residents of the remote island of Kitava
in Papua New Guinea [30] and the Tsimane [31] people
living in the Bolivian Amazon basin have been carefully
studied. Their diet is thought to be similar to what Stone Age
men ate 500,000 years ago, consisting largely of nuts,
berries, vegetables, eggs, insects, ﬁsh, and wild meat, but no
sugar, dairy, or reﬁned fat [32]. These people are remarkably
free of clinical cardiovascular disease, as deﬁned by clinical
history of heart attack or stroke, abnormal blood pressure,
reduced peripheral arterial pulses, abnormal electrocardio-
gram or elevated cholesterol [30,31]. More sophisticated
modern imaging methods have not been employed to
detect subclinical atherosclerosis in these very remote
communities.
It is tempting to extrapolate observations in these
hunter-gatherer societies, which may emulate Paleolithic
conditions to contemporary society, to help us combat the
epidemic of obesity, diabetes, hyperlipidemia, hypertension,
and atherosclerosis, but many confounding variables mustGLOBAL HEART, VOL. 9, NO. 2, 2014
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gest that inﬂammation and the presence of an increased in-
ﬂammatory burden or heightened inﬂammatory response
can predispose to the development of atherosclerosis
[33e35]. Despite the infrequency of heart attack and stroke,
hunter-gatherer people have an extremely high inﬂamma-
tory burden. Infection, trauma, childbirth, and starvation
often lead to death in hunter-gatherer populations in the ﬁrst
decades of life. Even though survivors may have lived into
old age, long enough to develop clinical manifestations of
atherosclerosis, we need further studies to better understand
the relation between diet, exercise, inﬂammation, and
heredity on the development of atherosclerosis.EARLY HOMINIDS AND BEYOND, TO THE ORIGINS
OF LIFE
Homo sapiens are thought to have emerged as a new species
about 200,000 years ago, but preservation of sufﬁcient soft
tissue in mummiﬁed human remains is unlikely to extend
much beyond the age of the Iceman, who was frozen into
an Alpine glacier approximately 5,300 years ago [23,28].
However, deoxyribonucleic acid (DNA) from fossilized
Neanderthals, whose species diverged from humans
approximately 500,000 years ago, has been sequenced
[36]. Spontaneous atherosclerosis occurs in many species
besides humans, including wild animals such as buffalo,
hippopotamus, cows, and non-human primates, both
vegetarians and meat eaters [37,38]. Fuster et al. [39] made
seminal observations in pigs regarding the critical interac-
tion between platelets and the arterial wall in the devel-
opment of atherosclerosis, noting that pigs with inherited
von Willebrand disease had less intimal proliferation and
much smaller atherosclerotic plaques than did pigs with
normal platelets. These observations underlie much of our
modern understanding of the pathophysiology of acute
coronary syndromes, including myocardial infarction, the
end stage of an atherosclerotic process that may have been
underway in a given individual for decades prior. Even
nonmammals such as birds [40], which are phylogeneti-
cally related to dinosaurs, can develop atherosclerosis,
perhaps dating the earliest genetic origins of atherosclerosis
to the Mesozoic era, 252 to 66 million years ago. It is
humbling to be reminded that we humans are wedged
developmentally together with nonhumans, closer to pigs
than chickens perhaps, in the longue durée picture of the
evolution of atherosclerosis.
Humans may always have had the genetic propensity
to develop atherosclerosis, with environmental inﬂuences
determining ﬁnal phenotypic expression. The recently ac-
quired ability to sequence the entire human genome is
having profound inﬂuence on our investigations of human
diseases, including atherosclerosis. Unlike many of the
hereditary cardiomyopathies and dysrhythmias, which are
single-gene disorders, genetic predisposition to athero-
sclerosis is due to multiple common genes, widely
distributed in the entire population, each genetic241
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polymorphism having limited effect on the ﬁnal phenotype
[41,42]. Genome-wide association studies have identiﬁed
more than 40 genetic risk variants associated with coronary
artery disease, but 10 of these variants occur in more than
75% of the population, and the risk effect of each variant is
relatively small, averaging an increased incidence of disease
of about 18% [43]. The nature of how these common
genetic polymorphisms interact with the environment to
produce atherosclerosis and clinical coronary artery disease
remains unexplained, but is the subject of intense investi-
gation. Most of the known genetic risk factors for athero-
sclerosis are linked by network analysis to lipid metabolism
and inﬂammation. The role of bacterial or viral infections,
particularly in the pre-antibiotic era, are uncertain.
Part of the answer may lie beyond the cell nucleus and
nuclear DNA. Mitochondrial DNA, located in the cytoplasm,
consists of only approximately 16,000 base pairs and encodes
only a fewproteins, but it does control adenosine triphosphate
and reactive oxygen species (ROS) production, thus having a
strong impact on cell proliferation. The mitochondrial aden-
osine triphosphatase inhibitory factor 1 triggers a ROS-
mediated retrograde prosurvival and proliferative response
[44] and innate immunity [29] affecting atherosclerosis.
Mitochondrial DNA, which is transmitted through female
oocytes, has a much higher mutation rate than nuclear DNA
does and may provide a more plausible explanation for the
relatively rapid changes apparent in the genetic regulation of
atherosclerotic processes [45]. Mitochondria regulate the
essentialﬂowof energy through the cell, generating adenosine
triphosphate and acetyl-coenzyme A, which together with
histone phosphorylation and acetylation, modulate nuclear
gene expression.
Perhaps a billion and a half years ago, mitochondria
evolved from aerobic bacteria, which colonized primordial
eukaryotic cells, enabling them to use oxygen to produce
energy more efﬁciently than with anaerobic glycolysis. The
inﬂuence of mitochondrial DNA occurs early in the athero-
sclerotic process, leading to impaired bioenergetics, pro-
moting atherosclerosis and hypercholesterolemia through
changes in cell proliferation and apoptosis [46], leading ul-
timately to unstable atherosclerotic plaques that are perhaps
vulnerable to rapid progression to occlude the vessel
lumen. These epigenetic processes are also under intense
investigation. Atherosclerosis is a complex disease. The
evolving ﬁelds of transcriptomics, proteomics, and metab-
olomics will enable us to unravel features of the human
genome and better understand its pathogenesis of athero-
sclerosis and perhaps identify new targets for treatment [47].AN EXPLOSION OF DATA
Relating the vast quantities of genomic data being generated
using next-generation sequencing to daily clinical practice
presents enormous challenges in medical informatics. Here
again, medical scientists may beneﬁt from the experience of
colleagues in social science who use the tool of prosopog-
raphy to investigate common characteristics of a historicalgroup, even members of pre-modern societies without
written records, to create a collective biography by analyzing
statistically relevant archeological and anthropological data
[48]. At some level, this process seems remarkably similar to
the sophisticated bioinformatics processes being used to
decipher the human genome. If we can recreate a vision of
man before writing was invented, perhaps we can decipher
the 5 billion gigabytes of information now being created in
modern society every 10 min to reduce the impact of
atherosclerosis on humans today [42].
Contemplating the enormity of the information and
knowledge about the stuff of life that has accumulated in the
last 10 years, following the billion years since the ﬁrst bac-
teria entered a eukaryotic cell, it is difﬁcult not to agree with
Francis Collins [49], a pioneer of the Human Genome
Project and director of the National Institutes of Health, who
said: “Scientists aren’t generally prone to effusiveness.We are
privately excited about our work, but in public we often, and
rightly, emphasize skepticism and caution. But there are
exceptional moments where skepticism is set aside, elec-
tricity ﬁlls the room, and a scientist with palpable passion
and ﬂashing eyes describes unabashedly a change in the
landscape that will have lasting signiﬁcance. Just a few
months into the new millennium, I had that experience.”PERSPECTIVE—THE LONGUE DURÉE APPROACH
Braudel might suggest that we reserve judgment on the
impact of the genomic and bioinformatics revolution on the
management of our patients with atherosclerosis until we
have had time to digest the ﬂood of new information. Ran-
domized controlled trials, registries, guidelines, and appro-
priate use criteria [50], all late 20th century inventions, are
essential pieces of the increasingly complex puzzle of
atherosclerosis. A tremendous amount of work remains to be
done to extract actionable components and translate them
for human use before we head into the examining room to
treat individual patients. Sequencing the entire human
genome surely will go down as a landmark of the 21st cen-
tury, as did Watson and Crick’s demonstration of the
structure of DNA in the 20th century and Darwin’s and
Mendel’s observations of genetics in the 19th century, but, in
the big picture, the impact of these advances on mankind is
just beginning [51]. It is an exciting beginning.
Atherosclerosis is not a recent phenomenon in human
history, nor is it exclusive toHomo sapiens. Indeed, the genetic
and biologic capacity for developing atherosclerosis may
involve processes that date to the very origins of life. In the
course of 250,000 years of human existence, our changing
relationship with our environment has led us to evolve, both
our genotypes and our phenotypes. Change was relatively
slow during the Paleolithic and early Agrarian eras, but has
progressed exponentially in the Modern era. It is estimated
that therewere fewer than250millionhumansonEarth 1,000
years ago. We now number more than 6 billion.
As we have progressed from living in subsistence com-
munities of hunter-forager-farmers to living as consumerGLOBAL HEART, VOL. 9, NO. 2, 2014
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societies in cities with many millions of inhabitants, fewer of
us are dying from starvation, from infections or trauma, or
during childbirth. “Prosperity” is spreading rapidly from the
developed to the developing world, bringing with it an aging
population afﬂicted with obesity, diabetes, hyperlipidemia,
hypertension, and nicotine addiction—all precursors or
accelerators of atherosclerosis. We humans will need to use
all our combined creative genius to contend with our new
environment, some of which we created ourselves, if we are
to survive as a species for another 250,000 years.
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